XCellCure is a revolutionary biotechnology company dedicated to transforming modern cardiac care and enabling quantitative, low-cost prevention. With their flagship product, the AMiAware Human Cardiovascular Disease Microarray, XCellCure is revolutionizing the prevention of recurrent heart attacks through patient-centered risk stratification using 13 groundbreaking biomarkers. XCellCure focuses on noninvasively diagnosing and prognosticating patients experiencing acute coronary symptoms to aid in patient monitoring, therapeutic selection, and ultimately prevent fatalities and reduce the morbidity associated with cardiovascular disease.

They are also introducing a range of cardiac devices for research, clinical, and point of care settings, designed to complement and enhance current care and improve patient quality of life. One notable product in their lineup is the AMiAware line of devices, offering a unique Signature of Disease that provides critical clinical evidence, empowering physicians to make accurate and swift decisions for patients with acute coronary syndromes. Pioneering the integration of 13 essential cardiac biomarkers into a user-friendly platform, XCellCure equips cardiologists with the decisive power to administer patient-centered therapy more rapidly than ever before.

Whether it's evaluating patients at hospitals, labs, physician offices, gyms, walk-in clinics, or emergency rooms, XCellCure's products play a crucial role in preventing future fatal heart attacks. Trust XCellCure to provide the information necessary for a healthier tomorrow